🇺🇸 FDA
Pipeline program

HER-2/neu peptide vaccine

MC1136

Phase 1 mab completed

Quick answer

HER-2/neu peptide vaccine for HER2-positive Breast Cancer is a Phase 1 program (mab) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Marker Therapeutics
Indication
HER2-positive Breast Cancer
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials